专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07727994B2 Methods of treating patients suffering from movement disorders 有权
标题翻译：治疗运动障碍患者的方法
公开(公告)号：US07727994B2
公开(公告)日：2010-06-01
申请号：US11326516
申请日：2006-01-06
申请人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
发明人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
IPC分类号： A61K31/522 , A61K31/505
CPC分类号： A61K31/522 , A61K9/0019 , A61K9/20 , A61K9/48 , A61K31/198 , A61K45/06
摘要： The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
摘要翻译：本发明涉及通过向有需要的患者施用有效量的一种或多种腺苷A 2A受体拮抗剂来治疗运动障碍的方法。本发明还提供降低L-DOPA在接受L-DOPA治疗的帕金森病治疗中的不良反应的方法。本发明进一步提供了通过将L-DOPA治疗与有效量的一种或多种腺苷A 2A受体拮抗剂组合（即L-DOPA备用效应）来治疗具有亚临床有效剂量的L-DOPA的帕金森病患者的方法和组合物，。本发明还提供了通过共同施用至少一种腺苷A 2A受体拮抗剂，L-DOPA和多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂来有效治疗帕金森病的方法。本发明还提供了延长帕金森病有效治疗的方法，通过单独或与多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂一起施用腺苷A2A受体拮抗剂，而无需先前或随后给予L-DOPA ，延迟或消除L-DOPA电机并发症。

2. 发明申请

US20060178379A1 Methods of treating patients suffering from movement disorders 有权
公开(公告)号：US20060178379A1
公开(公告)日：2006-08-10
申请号：US11326414
申请日：2006-01-06
申请人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
发明人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
IPC分类号： A61K31/522 , A61K31/198 , A61K31/137
CPC分类号： A61K31/522 , A61K9/0019 , A61K9/20 , A61K9/48 , A61K31/198 , A61K45/06
摘要： The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.

3. 发明授权

US07727993B2 Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy 有权
标题翻译：管理腺苷A2A受体拮抗剂以减少或抑制帕金森病治疗的副作用
公开(公告)号：US07727993B2
公开(公告)日：2010-06-01
申请号：US11326414
申请日：2006-01-06
申请人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
发明人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
IPC分类号： A61K31/522 , A61K31/505
CPC分类号： A61K31/522 , A61K9/0019 , A61K9/20 , A61K9/48 , A61K31/198 , A61K45/06
摘要： The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
摘要翻译：本发明涉及通过向有需要的患者施用有效量的一种或多种腺苷A 2A受体拮抗剂来治疗运动障碍的方法。本发明还提供降低L-DOPA在接受L-DOPA治疗的帕金森病治疗中的不良反应的方法。本发明进一步提供了通过将L-DOPA治疗与有效量的一种或多种腺苷A 2A受体拮抗剂组合（即L-DOPA备用效应）来治疗具有亚临床有效剂量的L-DOPA的帕金森病患者的方法和组合物，。本发明还提供了通过共同施用至少一种腺苷A 2A受体拮抗剂，L-DOPA和多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂来有效治疗帕金森病的方法。本发明还提供了延长帕金森病有效治疗的方法，通过单独或与多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂一起施用腺苷A2A受体拮抗剂，而无需先前或随后给予L-DOPA ，延迟或消除L-DOPA电机并发症。

4. 发明申请

US20060148827A1 Methods of treating patients suffering from movement disorders 有权
标题翻译：治疗运动障碍患者的方法
公开(公告)号：US20060148827A1
公开(公告)日：2006-07-06
申请号：US11326516
申请日：2006-01-06
申请人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
发明人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
IPC分类号： A61K31/522 , A61K31/198 , A61K31/137
CPC分类号： A61K31/522 , A61K9/0019 , A61K9/20 , A61K9/48 , A61K31/198 , A61K45/06
摘要： The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
摘要翻译：本发明涉及通过向有需要的患者施用有效量的一种或多种腺苷A 2A 2受体拮抗剂来治疗运动障碍的方法。本发明还提供降低L-DOPA在接受L-DOPA治疗的帕金森病治疗中的不良反应的方法。本发明进一步提供了通过将L-DOPA治疗与有效量的一种或多种腺苷A 2A受体拮抗剂组合（用于治疗患有亚临床有效剂量的L-DOPA）的帕金森病患者的方法和组合物即L-DOPA保护作用）。本发明还提供了通过共同施用至少一种腺苷A 2A受体拮抗剂，L-DOPA和多巴胺激动剂和/或COMT抑制剂和/或MAO来有效治疗帕金森病的方法抑制剂。本发明还提供了通过单独或与多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂一起施用腺苷A 2A受体拮抗剂而延长帕金森病有效治疗的方法，而没有之前或之后的L-DOPA给药，延迟或去除L-DOPA运动并发症。

5. 发明申请

US20120122897A1 METHODS OF TREATING PATIENTS SUFFERING FROM MOVEMENT DISORDERS 审中-公开
标题翻译：治疗运动障碍患者的方法
公开(公告)号：US20120122897A1
公开(公告)日：2012-05-17
申请号：US13297341
申请日：2011-11-16
申请人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
发明人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
IPC分类号： A61K31/522 , A61P25/00 , A61P25/14 , A61P25/16
CPC分类号： A61K31/522 , A61K9/0019 , A61K9/20 , A61K9/48 , A61K31/198 , A61K45/06
摘要： Methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof and methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. Also, methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA with an effective amount of one or more adenosine A2A receptor antagonists, optionally with a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.
摘要翻译：通过向有需要的患者施用有效量的一种或多种腺苷A2A受体拮抗剂和降低L-DOPA在接受L-DOPA治疗帕金森病的患者中的不利影响的方法来治疗运动障碍的方法。此外，用有效量的一种或多种腺苷A2A受体拮抗剂，任选地与多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂治疗具有亚临床有效剂量的L-DOPA的帕金森病患者的方法和组合物。

6. 发明申请

US20060058512A1 Process for producing humanized chimera antibody 审中-公开
标题翻译：生产人源化嵌合体抗体的方法
公开(公告)号：US20060058512A1
公开(公告)日：2006-03-16
申请号：US11228319
申请日：2005-09-19
申请人： Kenya Shitara , Nobuo Hanai , Mamoru Hasegawa , Hiromasa Miyaji , Yoshihisa Kuwana
发明人： Kenya Shitara , Nobuo Hanai , Mamoru Hasegawa , Hiromasa Miyaji , Yoshihisa Kuwana
IPC分类号： A61K39/395 , C07K16/44
CPC分类号： C07K16/3084 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K16/462 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/02
摘要： A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.
摘要翻译：公开了人源化嵌合体抗体，包含人源化嵌合体抗体和药学上可接受的载体的药物组合物，以及治疗癌症的方法，其包括向患者施用药学上可接受量的人源化嵌合体抗体。

7. 发明授权

US5939532A Humanized antibodies to ganglioside GM.sub.2 失效
公开(公告)号：US5939532A
公开(公告)日：1999-08-17
申请号：US483528
申请日：1995-06-07
申请人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
发明人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
IPC分类号： C07K16/18 , C07K16/46 , C12P21/08 , C07K16/00 , C12N5/00 , C12P21/06
CPC分类号： C07K16/18 , C07K16/464 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00
摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

8. 发明申请

US20060058320A1 [1,2,4] Triazolo[1,5-c]pyrimidine derivatives 审中-公开
标题翻译： [1,2,4]三唑并[1,5-c]嘧啶衍生物
公开(公告)号：US20060058320A1
公开(公告)日：2006-03-16
申请号：US10528452
申请日：2003-09-24
申请人： Kyoichiro Iida , Takamasa Sugita , Shizuo Shiozaki , Tomoyuki Kanda , Yoshihisa Kuwana , Junichi Shimada
发明人： Kyoichiro Iida , Takamasa Sugita , Shizuo Shiozaki , Tomoyuki Kanda , Yoshihisa Kuwana , Junichi Shimada
IPC分类号： A61K31/519 , C07D487/04
CPC分类号： C07D487/04
摘要： The present invention provides [1,2,4]triazolo[1,5-c]pyrimidine derivatives or pharmaceutically acceptable salts thereof which have adenosine A2A receptor antagonism and are useful for treating and/or preventing a disease induced by hyperactivity of an adenosine A2A receptor, the derivatives being represented by formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R2 represents a hydrogen atom, halogen, lower alkyl, lower alkanoyl, aroyl, substituted or unsubstituted aryl, or a substituted or unsubstituted aromatic heterocyclic group; R3 represents lower alkyl, lower cycloalkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aryl, or a substituted or unsubstituted aromatic heterocyclic group; and Q represents a hydrogen atom or 3,4-dimethoxybenzyl).
摘要翻译：本发明提供具有腺苷A 2A 2受体拮抗作用的[1,2,4]三唑并[1,5-c]嘧啶衍生物或其药学上可接受的盐，可用于治疗和/或预防由腺苷A 2A受体的多动症引起的疾病，该衍生物由式（I

9. 发明申请

US20060057139A1 Process for producing humanized chimera antibody 审中-公开
公开(公告)号：US20060057139A1
公开(公告)日：2006-03-16
申请号：US11228293
申请日：2005-10-25
申请人： Kenya Shitara , Nobuo Hanai , Mamoru Hasegawa , Hiromasa Miyaji , Yoshihisa Kuwana
发明人： Kenya Shitara , Nobuo Hanai , Mamoru Hasegawa , Hiromasa Miyaji , Yoshihisa Kuwana
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C12N5/06
CPC分类号： C07K16/3084 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K16/462 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/02
摘要： A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.

10. 发明授权

US5866692A Process for producing humanized chimera antibody 失效
公开(公告)号：US5866692A
公开(公告)日：1999-02-02
申请号：US454680
申请日：1995-05-31
申请人： Kenya Shitara , Nobuo Hanai , Mamoru Hasegawa , Hiromasa Miyaji , Yoshihisa Kuwana
发明人： Kenya Shitara , Nobuo Hanai , Mamoru Hasegawa , Hiromasa Miyaji , Yoshihisa Kuwana
IPC分类号： A61K36/00 , A61K38/00 , A61P35/00 , C07K7/06 , C07K7/08 , C07K14/00 , C07K16/00 , C07K16/18 , C07K16/30 , C07K16/32 , C07K16/46 , C07K19/00 , C12N5/10 , C12N15/00 , C12N15/09 , C12N15/12 , C12N15/13 , C12N15/62 , C12P21/08 , C12R1/91 , C12N15/11
CPC分类号： C07K16/3084 , C07K16/18 , C07K16/462 , A61K2039/505 , A61K38/00 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/02
摘要： A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of said humanized chimera antibody, are disclosed.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式